Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VOLTAREN ARTHRITIS PAIN vs NALBUPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Relief of pain and inflammation associated with osteoarthritis,Relief of pain and inflammation associated with rheumatoid arthritis,Relief of pain and inflammation associated with ankylosing spondylitis,Acute pain (including migraine),Dysmenorrhea
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Oral: 50 mg twice daily or 75 mg twice daily for osteoarthritis; immediate-release: 50 mg three times daily for rheumatoid arthritis. Maximum daily dose: 150 mg.
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
Approximately 2 hours; terminal half-life may be prolonged in elderly (up to 4 hours) or hepatic impairment.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Hepatic metabolism via CYP2C9; also undergoes conjugation (glucuronidation) and hydroxylation.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
>99% bound to albumin.
Approximately 50% bound to plasma proteins, primarily albumin.
0.1–0.2 L/kg; primarily distributes to synovial fluid (concentrations up to 50% of plasma).
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Oral: 100% (immediate-release); topical: approximately 6% systemic absorption.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
GFR >30 m L/min: no adjustment. GFR 10-30 m L/min: dose reduction to 50 mg once daily or avoid use. GFR <10 m L/min: contraindicated.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 75 mg/day). Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
For juvenile idiopathic arthritis: 1-2 mg/kg/day in 2-3 divided doses, maximum 3 mg/kg/day or 150 mg/day. For children <1 year: not recommended.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Start at lowest effective dose (e.g., 50 mg once daily). Increase cautiously; maximum 100 mg/day. Monitor renal function and GI bleeding risk.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure and edema; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; ophthalmic effects; hepatic effects; asthma; masking of inflammation and fever.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; pregnancy (third trimester); history of gastrointestinal bleeding or perforation related to previous NSAID therapy; active peptic ulcer disease; severe heart failure; known hypersensitivity to diclofenac or any component of the product.
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
No specific food interactions with topical diclofenac. However, high-fat meals may increase systemic absorption if gel is applied over large areas; advise avoiding excessive intake of fatty foods when using large doses. Alcohol may increase risk of gastrointestinal irritation if oral NSAIDs are taken concurrently; avoid excessive alcohol consumption.
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
First trimester: Risk of miscarriage and congenital malformations (cardiac, gastroschisis) increased; avoid use. Second trimester: Possible oligohydramnios and fetal renal impairment. Third trimester: High risk of premature closure of ductus arteriosus, persistent pulmonary hypertension, oligohydramnios; contraindicated after 30 weeks gestation.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Limited excretion into breast milk (M/P ratio approximately 0.02-0.04). Considered compatible with breastfeeding due to low infant dose (<0.1% of maternal weight-adjusted dose); monitor infant for gastrointestinal effects.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
No specific pharmacokinetic dose adjustments established; avoid or use lowest effective dose for shortest duration. Increased renal clearance in pregnancy may reduce drug levels, but risks outweigh benefits; generally not recommended.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
Voltaren Arthritis Pain (diclofenac sodium topical gel 1%) is indicated for osteoarthritis of superficial joints (e.g., hands, knees). Apply 2-4 g per affected joint four times daily. Maximum total daily dose is 32 g for upper extremities and 16 g for lower extremities. Avoid contact with eyes and mucous membranes. Use for at least 4 weeks to assess efficacy. Do not apply to open wounds or infected areas. Concurrent use of oral NSAIDs increases risk of GI and renal toxicity; consider cumulative dose. Monitor for signs of local site reactions or systemic effects, especially in elderly or those with renal impairment.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Apply the gel to clean, dry skin only on the painful joint. Do not use on broken skin, cuts, or infections.,Use the enclosed dosing card to measure the correct amount: 2 to 4 grams per joint, up to four times daily.,Do not exceed 32 grams per day for hands, wrists, elbows, or 16 grams per day for knees, ankles, or feet.,Wash hands immediately after applying unless treating hands; then wait 1 hour before washing.,Allow the gel to dry for several minutes before covering the area with clothing or gloves.,Avoid applying sunscreen, cosmetics, lotions, or other topical products to the treated skin.,Do not use heat (e.g., heating pad) or bandage the treated area.,Inform your doctor if you have a history of stomach ulcers, bleeding, kidney disease, or are taking blood thinners.,Stop use and contact your doctor if you develop a rash, swelling, or worsening pain in the treated area.,Keep out of reach of children and pets. In case of accidental ingestion, seek medical attention.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
No interactions on record
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VOLTAREN ARTHRITIS PAIN vs NALBUPHINE, answered by our medical review team.
VOLTAREN ARTHRITIS PAIN is a NSAID (Topical) that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.. NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VOLTAREN ARTHRITIS PAIN and NALBUPHINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VOLTAREN ARTHRITIS PAIN is: Oral: 50 mg twice daily or 75 mg twice daily for osteoarthritis; immediate-release: 50 mg three times daily for rheumatoid arthritis. Maximum daily dose: 150 mg.. The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VOLTAREN ARTHRITIS PAIN and NALBUPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VOLTAREN ARTHRITIS PAIN is classified as Category C. First trimester: Risk of miscarriage and congenital malformations (cardiac, gastroschisis) increased; avoid use. Second trimester: Possible oligohydramnios and fetal renal impairme. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.